Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)

Vilija G Jokubaitis; Raed Alroughani; Ayse Altintas; Sara Eichau; Stella Hughes; Barbara Willekens; Dana Horakova; Eva Kubala Havrdova; Serkan Ozakbas; Cavit Boz; Mario Habek; Tomas Kalincik; Izanne Roos; Masoud Etemadifar; Marek Peterka; Jeannette Lechner-Scott; Jose E Meca-Lallana; Zuzana Rous; Jana Houskova; Alexandre Prat; Marc Girard; Radek Ampapa; Katherine Buzzard; Olga Skibina; Nevin A John; Allan G Kermode; Marzena J Fabis-Pedrini; Matteo Foschi; Andrea Surcinelli; Yolanda Blanco; Seyed Mohammad Baghbanian; Oliver Gerlach; Richard Macdonell; Zbysek Pavelek; Pavel Stourac; Pamela McCombe; Guy Laureys; Helmut Butzkueven; Anneke van der Walt; Orla Gray; MSBase Study Investigators

doi:10.1177/13524585251349125

Back

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)

Journal article

Open access

Peer reviewed

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)

Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Barbara Willekens, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Cavit Boz, …

Multiple sclerosis, Vol.31(9), pp.1088-1101

2025

DOI: https://doi.org/10.1177/13524585251349125

PMID: 40621862

Files and links (1)

pdf

Published797.23 kBDownload View

CC BY V4.0, Open Access

Abstract

neonatal outcomes

Multiple sclerosis

neuromyelitis optica spectrum disorder

disease-modifying therapy

pregnancy

Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure. To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry. We report summary statistics for data collected between May 2020 and August 2024. A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen. This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.

Details

Title: Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)
Authors/Creators: Vilija G Jokubaitis - Monash University
Raed Alroughani - Amiri Hospital
Ayse Altintas - Koç University
Sara Eichau - Hospital Universitario Virgen Macarena
Stella Hughes - Royal Victoria Hospital
Barbara Willekens - Antwerp University Hospital
Dana Horakova - Charles University
Eva Kubala Havrdova - Charles University
Serkan Ozakbas - İzmir University of Economics
Cavit Boz - Karadeniz Technical University
Mario Habek - University of Zagreb
Tomas Kalincik - The Royal Melbourne Hospital
Izanne Roos - The Royal Melbourne Hospital
Masoud Etemadifar - Isfahan University of Medical Sciences
Marek Peterka - Charles University
Jeannette Lechner-Scott - Hunter Medical Research Institute
Jose E Meca-Lallana - Pontifícia Universidade Católica de São Paulo
Zuzana Rous - University Hospital Olomouc
Jana Houskova - Nemocnice České Budějovice
Alexandre Prat - Université de Montréal
Marc Girard - Université de Montréal
Radek Ampapa - Hospital Jihlava
Katherine Buzzard - Box Hill Hospital
Olga Skibina - Box Hill Hospital
Nevin A John - Monash University
Allan G Kermode - Murdoch University, Institute for Immunology and Infectious Diseases
Marzena J Fabis-Pedrini - Monash University
Matteo Foschi - Ospedale "Santa Maria delle Croci" di Ravenna
Andrea Surcinelli - Ospedale "Santa Maria delle Croci" di Ravenna
Yolanda Blanco - Hospital Clínic de Barcelona
Seyed Mohammad Baghbanian - Mazandaran University of Medical Sciences
Oliver Gerlach - Zuyderland Medisch Centrum
Richard Macdonell - Austin Health
Zbysek Pavelek - University Hospital Hradec Králové
Pavel Stourac - Masaryk University
Pamela McCombe - The University of Queensland
Guy Laureys - Ghent University Hospital
Helmut Butzkueven - Monash University
Anneke van der Walt - Monash University
Orla Gray - South Eastern Health and Social Care Trust
MSBase Study Investigators
Publication Details: Multiple sclerosis, Vol.31(9), pp.1088-1101
Publisher: SAGE Publications
Number of pages: 14
Identifiers: 991005795470407891
Murdoch Affiliation: Institute for Immunology and Infectious Diseases; Personalised Medicine Centre
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

17 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.203 Neuromuscular Disorders; 1.203.147 Multiple Sclerosis
Web Of Science research areas: Clinical Neurology; Neurosciences
ESI research areas: Neuroscience & Behavior